BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28104820)

  • 1. Immune checkpoint inhibitors in malignancies with mismatch repair deficiency: a review of the state of the current knowledge.
    Naboush A; Roman CA; Shapira I
    J Investig Med; 2017 Apr; 65(4):754-758. PubMed ID: 28104820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
    Lee V; Murphy A; Le DT; Diaz LA
    Oncologist; 2016 Oct; 21(10):1200-1211. PubMed ID: 27412392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
    Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
    Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.
    Cohen R; Pellat A; Boussion H; Svrcek M; Lopez-Trabada D; Trouilloud I; Afchain P; André T
    Bull Cancer; 2019 Feb; 106(2):137-142. PubMed ID: 30327191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.
    Viale G; Trapani D; Curigliano G
    Biomed Res Int; 2017; 2017():4719194. PubMed ID: 28770222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate.
    Willis JA; Reyes-Uribe L; Chang K; Lipkin SM; Vilar E
    Clin Cancer Res; 2020 Jan; 26(1):11-17. PubMed ID: 31383734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Immune Biology of Microsatellite-Unstable Cancer.
    Kloor M; von Knebel Doeberitz M
    Trends Cancer; 2016 Mar; 2(3):121-133. PubMed ID: 28741532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Microsatellite instability (MSI): best predictor of effectiveness of immune checkpoint inhibitors (ICKi)? Focus on MSI by Bulletin du Cancer].
    André T
    Bull Cancer; 2019 Feb; 106(2):91-93. PubMed ID: 30711199
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues.
    Sahin IH; Ciombor KK; Diaz LA; Yu J; Kim R
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35658496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [MSI Metastatic solid tumors treatment and immunotherapies].
    Bouchez C; Kempf E; Tournigand C
    Bull Cancer; 2019 Feb; 106(2):143-150. PubMed ID: 30737018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy and patients treated for cancer with microsatellite instability.
    Colle R; Cohen R; Cochereau D; Duval A; Lascols O; Lopez-Trabada D; Afchain P; Trouilloud I; Parc Y; Lefevre JH; Fléjou JF; Svrcek M; André T
    Bull Cancer; 2017 Jan; 104(1):42-51. PubMed ID: 27979364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.
    Bouffet E; Larouche V; Campbell BB; Merico D; de Borja R; Aronson M; Durno C; Krueger J; Cabric V; Ramaswamy V; Zhukova N; Mason G; Farah R; Afzal S; Yalon M; Rechavi G; Magimairajan V; Walsh MF; Constantini S; Dvir R; Elhasid R; Reddy A; Osborn M; Sullivan M; Hansford J; Dodgshun A; Klauber-Demore N; Peterson L; Patel S; Lindhorst S; Atkinson J; Cohen Z; Laframboise R; Dirks P; Taylor M; Malkin D; Albrecht S; Dudley RW; Jabado N; Hawkins CE; Shlien A; Tabori U
    J Clin Oncol; 2016 Jul; 34(19):2206-11. PubMed ID: 27001570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy.
    Chang L; Chang M; Chang HM; Chang F
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):e15-e21. PubMed ID: 28877075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsatellite instability/mismatch repair deficiency in pancreatic cancers: the same or different?
    Luchini C; Grant RC; Scarpa A; Gallinger S
    Gut; 2021 Oct; 70(10):1809-1811. PubMed ID: 33468535
    [No Abstract]   [Full Text] [Related]  

  • 20. Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.
    Wang Z; Zhao J; Wang G; Zhang F; Zhang Z; Zhang F; Zhang Y; Dong H; Zhao X; Duan J; Bai H; Tian Y; Wan R; Han M; Cao Y; Xiong L; Liu L; Wang S; Cai S; Mok TSK; Wang J
    Cancer Res; 2018 Nov; 78(22):6486-6496. PubMed ID: 30171052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.